



March 22, 2016

## **Mirna Therapeutics to Host Conference Call and Webcast of Fourth Quarter and Full Year 2015 Financial Results on March 29, 2016**

AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that the Company will host a conference call and live webcast on Tuesday, March 29, 2016 at 5:00 p.m. ET to report its fourth quarter and full year 2015 financial results and provide a clinical program and business update.

To access the call, participants should dial 877-407-9079 (US & Canada) or 201-493-6746 (international) at least 10 minutes prior to the start of the call. The call will be webcast live and may be accessed from the [Events & Presentations](#) section of the Company's website. An archived version of the webcast will be available for replay following the event.

### **About Mirna Therapeutics, Inc.**

Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The Company was founded in 2007 and is located in Austin, Texas.

For more information, visit [www.mirnarx.com](http://www.mirnarx.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160322005745/en/>

### **Investors**

The Trout Group  
Josh Barer, 646-378-2948  
[jbarer@troutgroup.com](mailto:jbarer@troutgroup.com)

or

### **Media**

BMC Communications  
Amy Bonanno, 646-513-3117  
[abonanno@bmccommunications.com](mailto:abonanno@bmccommunications.com)

Source: Mirna Therapeutics, Inc.

News Provided by Acquire Media